Janus Pharmaceuticals Announces IND Filing For JA-001
10/19/2005 5:13:12 PM
LOS ANGELES--(BUSINESS WIRE)--April 4, 2005--
Cream Formulation of Anti-Zoster Drug to Be Evaluated in Phase 1 Studies in the United States
Janus Pharmaceuticals Inc. (Janus) announced the filing of an Investigational New Drug application for a topical formulation of an anti-viral product with previously demonstrated activity against the varicella zoster virus (VZV) in both preclinical and clinical studies. Janus plans to conduct clinical studies evaluating the safety and efficacy of JA-001 (also known as ARYS-01 cream) a topical formulation of sorivudine for the treatment of herpes zoster infections.
Sorivudine is an antiviral nucleoside analog which is transported into viral-infected cells and converted to monophosphate analogs by virus-encoded thymidine kinases. Sorivudine was originally discovered by Yamasa Corporation of Chiba, Japan, and is being developed as a topical formulation by Janus under a joint development agreement with aRigen Inc. of Tokyo, Japan. aRigen has filed several patents to cover the production method and use of the topical formulation for the treatment of herpes zoster.
comments powered by